These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

876 related articles for article (PubMed ID: 33602943)

  • 1. Duchenne muscular dystrophy.
    Duan D; Goemans N; Takeda S; Mercuri E; Aartsma-Rus A
    Nat Rev Dis Primers; 2021 Feb; 7(1):13. PubMed ID: 33602943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duchenne muscular dystrophy: pathogenesis and promising therapies.
    Chang M; Cai Y; Gao Z; Chen X; Liu B; Zhang C; Yu W; Cao Q; Shen Y; Yao X; Chen X; Sun H
    J Neurol; 2023 Aug; 270(8):3733-3749. PubMed ID: 37258941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in genetic therapeutic strategies for Duchenne muscular dystrophy.
    Guiraud S; Chen H; Burns DT; Davies KE
    Exp Physiol; 2015 Dec; 100(12):1458-67. PubMed ID: 26140505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.
    Siemionow M; Langa P; Harasymczuk M; Cwykiel J; Sielewicz M; Smieszek J; Heydemann A
    Stem Cells Transl Med; 2021 Oct; 10(10):1406-1418. PubMed ID: 34291884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR Therapeutics for Duchenne Muscular Dystrophy.
    Erkut E; Yokota T
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47.
    Heier CR; McCormack NM; Tully CB; Novak JS; Newell-Stamper BL; Russell AJ; Fiorillo AA
    J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):940-954. PubMed ID: 36628607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Frontline studies on Duchenne muscular dystrophy treatment].
    Matsuo M
    No To Hattatsu; 2009 Mar; 41(2):92-5. PubMed ID: 19517771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of dystrophin, the protein product of the Duchenne muscular dystrophy gene.
    Hoffman EP
    FEBS J; 2020 Sep; 287(18):3879-3887. PubMed ID: 32608079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies.
    Hoffman EP
    Acta Myol; 2020 Dec; 39(4):179-186. PubMed ID: 33458572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mouse model of Duchenne muscular dystrophy carrying a multi-exonic
    Wong TWY; Ahmed A; Yang G; Maino E; Steiman S; Hyatt E; Chan P; Lindsay K; Wong N; Golebiowski D; Schneider J; Delgado-Olguín P; Ivakine EA; Cohn RD
    Dis Model Mech; 2020 Sep; 13(9):. PubMed ID: 32988972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The golden retriever model of Duchenne muscular dystrophy.
    Kornegay JN
    Skelet Muscle; 2017 May; 7(1):9. PubMed ID: 28526070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients.
    Duan D
    Hum Gene Ther; 2018 Jul; 29(7):733-736. PubMed ID: 29463117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Genetic Diagnosis and Molecular Therapies for Duchenne Muscular Dystrophy].
    Takeshima Y
    Rinsho Byori; 2015 Oct; 63(10):1194-201. PubMed ID: 26897856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R; Yokota T
    Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mutation-specific treatments for Duchenne muscular dystrophy].
    Matsuo M; Takeshima Y
    Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy.
    Koo T; Wood MJ
    Hum Gene Ther; 2013 May; 24(5):479-88. PubMed ID: 23521559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic developments for Duchenne muscular dystrophy.
    Verhaart IEC; Aartsma-Rus A
    Nat Rev Neurol; 2019 Jul; 15(7):373-386. PubMed ID: 31147635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.